ClinicalTrials.gg
RecruitingNCT07627750ROC-IONMUpdated Oct 16, 2026

Low-Dose Rocuronium Maintenance During Spine Surgery With Intraoperative Neurophysiological Monitoring

An interventional study of Low-Dose Rocuronium Maintenance and Rocuronium in Spine Surgery, Intraoperative Neurophysiological Monitoring and Neuromuscular Blockade, sponsored by Bach Mai Hospital. Recruiting at 1 site in Vietnam. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Bach Mai Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Oct 16, 2026Now RecruitingFirst site in Vietnam+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This randomized controlled trial will compare two strategies for rocuronium use during general anesthesia for spine surgery with intraoperative neurophysiological monitoring. Participants undergoing spine surgery under general anesthesia with motor evoked potential and/or somatosensory evoked potential monitoring will be randomized to either low-dose rocuronium maintenance targeting a train-of-four ratio of 0.60 to less than 0.90, or no rocuronium maintenance after induction.

The main objective is to compare the effects of these two strategies on the quality of intraoperative neurophysiological monitoring, especially motor evoked potential signals. Secondary objectives include comparing surgical field conditions, unwanted patient movement, emergence and extubation times, early respiratory events, and new postoperative neurological deficits.

The study will be conducted at the Center for Anesthesia and Surgical Intensive Care, Bach Mai Hospital, Hanoi, Vietnam. The planned sample size is 62 participants, with 31 participants in each group.

Read the detailed description

Intraoperative neurophysiological monitoring is commonly used during complex spine surgery to help detect early neurological injury. Motor evoked potentials are particularly sensitive to neuromuscular blockade. Avoiding maintenance neuromuscular blockade may improve motor evoked potential signal quality, but may increase the risk of unwanted patient movement and suboptimal surgical field conditions. Conversely, low-dose rocuronium maintenance may improve surgical conditions, but may reduce motor evoked potential amplitude if neuromuscular blockade is excessive.

This trial will evaluate whether low-dose rocuronium maintenance, titrated by quantitative neuromuscular monitoring, can preserve intraoperative neurophysiological monitoring quality while improving surgical field conditions compared with discontinuation of rocuronium after induction.

All participants will receive standardized total intravenous anesthesia with propofol-based maintenance, bispectral index monitoring, quantitative train-of-four monitoring, and intraoperative neurophysiological monitoring. Rocuronium will be administered for tracheal intubation in both groups. In the low-dose maintenance group, rocuronium will be titrated to maintain a train-of-four ratio from 0.60 to less than 0.90. In the no-maintenance group, no additional rocuronium will be given after induction unless predefined safety rescue is required.

The primary outcome will be intraoperative motor evoked potential signal quality, including mean motor evoked potential amplitude. Secondary outcomes will include successful motor evoked potential recording, motor evoked potential warning events, somatosensory evoked potential stability, surgical field condition, unwanted patient movement, time to emergence, time to extubation, early postoperative respiratory events, and new postoperative neurological deficits.

02

Conditions studied

  • Spine Surgery
  • Intraoperative Neurophysiological Monitoring
  • Neuromuscular Blockade

Keywords

  • Rocuronium
  • Motor Evoked Potentials
  • Somatosensory Evoked Potentials
  • Train-of-Four Ratio
  • Spine Surgery
  • Intraoperative Neurophysiological Monitoring
  • Total Intravenous Anesthesia
03

In context

Lead sponsor

Bach Mai Hospital is the lead sponsor of 10 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 16, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18 years or older.
  • Patients scheduled for spine surgery under general anesthesia.
  • Patients undergoing spine surgery with intraoperative neurophysiological monitoring, including motor evoked potentials and/or somatosensory evoked potentials.
  • Patients who agree to participate in the study and provide written .

Exclusion criteria

Exclusion Criteria:

  • Pre-existing central or peripheral neurological disease that may affect intraoperative neurophysiological monitoring, such as quadriplegia, persistent sensory disorder, sequelae of stroke, or polyneuropathy.
  • History of epilepsy or electroencephalographic disorder.
  • Use of neuropsychiatric drugs, strong sedatives, or drugs affecting neuromuscular or neurological conduction within 48 hours before surgery.
  • Decompensated cardiovascular disease or severe respiratory disease that may affect emergence or anesthetic drug metabolism.
  • to intraoperative neurophysiological monitoring.
  • Contraindication to rocuronium.
  • Refusal to participate or withdrawal of consent at any time.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
62 participants (estimated)

Study arms

  • Experimental
    Low-Dose Rocuronium Maintenance

    Participants in this group will receive rocuronium for tracheal intubation followed by low-dose rocuronium maintenance during surgery. Rocuronium will be titrated using quantitative train-of-four monitoring to maintain a train-of-four ratio from 0.60 to less than 0.90. All participants will receive standardized total intravenous anesthesia and intraoperative neurophysiological monitoring.

    Drug: Low-Dose Rocuronium Maintenance

  • Active comparator
    No Rocuronium Maintenance After Induction

    Participants in this group will receive rocuronium for tracheal intubation only. No maintenance rocuronium will be administered after induction. Additional rocuronium may be given only as predefined safety rescue if clinically necessary. All participants will receive standardized total intravenous anesthesia and intraoperative neurophysiological monitoring.

    Drug: Rocuronium

Interventions

  • Rocuronium will be administered for tracheal intubation and then maintained at a low dose during surgery. The infusion will be titrated according to quantitative train-of-four monitoring to maintain a train-of-four ratio from 0.60 to less than 0.90.

  • Rocuronium will be administered only for tracheal intubation during induction of anesthesia. No maintenance rocuronium will be administered after induction, except for predefined safety rescue if clinically necessary.

    Also known as: Rocuronium for Intubation Only

06

What researchers measure

Primary outcomes

  1. Mean Intraoperative Motor Evoked Potential Amplitude

    Mean intraoperative motor evoked potential amplitude, measured in microvolts, recorded from predefined target muscles during spine surgery. The mean of three consecutive technically acceptable responses will be used at standardized intraoperative time points after stabilization of anesthesia and physiologic parameters.

    Time frame: From baseline intraoperative neurophysiological monitoring after patient positioning to the final intraoperative neurophysiological monitoring recording before wound closure

Secondary outcomes

  1. Successful Motor Evoked Potential Recording

    Proportion of participants with successful intraoperative motor evoked potential recording from at least one predefined target muscle.

    Time frame: During surgery

  2. Motor Evoked Potential Warning Events

    Number of intraoperative motor evoked potential warning events, defined as a decrease of 50 percent or more in amplitude from baseline lasting more than 5 minutes and not attributable to surgical manipulation after correction of physiologic and technical factors.

    Time frame: During surgery

  3. Surgical Field Condition

    Surgical field condition assessed using the Leiden-Surgical Rating Scale, ranging from 1 to 5, with higher scores indicating better surgical conditions.

    Time frame: During surgery

  4. Unwanted Patient Movement

    Occurrence and number of unwanted patient movement events that affect surgical manipulation or require anesthetic or neuromuscular blockade adjustment.

    Time frame: During surgery

  5. Time to Extubation

    Time from discontinuation of maintenance anesthetic infusion to safe tracheal extubation, measured in minutes.

    Time frame: From discontinuation of maintenance anesthesia to tracheal extubation

  6. New Postoperative Neurological Deficit

    Occurrence of new postoperative motor or sensory neurological deficit assessed in the post-anesthesia care unit and within 24 to 48 hours after surgery.

    Time frame: Post-anesthesia care unit and 24 to 48 hours after surgery

  7. Somatosensory Evoked Potential Stability

    Proportion of intraoperative monitoring time without significant somatosensory evoked potential changes, defined as latency increase of 10 percent or more or amplitude decrease of 50 percent or more from baseline lasting more than 5 minutes and not attributable to surgical manipulation.

    Time frame: During surgery

  8. Time to Emergence

    Time from discontinuation of maintenance anesthetic infusion to eye opening on verbal command, measured in minutes.

    Time frame: From discontinuation of maintenance anesthesia to eye opening on verbal command

  9. Early Postoperative Respiratory Events

    Occurrence of early respiratory events, including oxygen desaturation below 92 percent, laryngospasm, bronchospasm, sputum obstruction, or delayed extubation due to respiratory muscle weakness.

    Time frame: During emergence and within 60 minutes after arrival in the post-anesthesia care unit

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be publicly shared because the study involves sensitive clinical and perioperative data. Data are protected by privacy and ethical restrictions. De-identified aggregate data may be available from the corresponding author upon reasonable request and with approval from the relevant ethics committee.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2026 (actual). Primary completion is estimated for Dec 2028, 26 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Oct 2026, on Oct 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2026
First posted
Jun 4, 2026
StartActual
Oct 7, 2026was Jun 2026
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2028
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 16, 2026
Sites
1 site added — first site in Vietnam
Show site
  • Bach Mai Hospital · Hanoi, Vietnam
Oct 16, 2026
Start date
Jun 2026→Oct 7, 2026 (actual)
Oct 16, 2026
Eligibility
1 inclusion criterion edited, 2 added; 2 exclusion criteria edited, 3 added
What changed in the criteria
Inclusion criteria
  • AddedPatients aged 18 years or older.
  • AddedPatients scheduled for spine surgery under general anesthesia.
  • Edited- 1. Patients aged 18 years or older. 2. Patients scheduled for spine surgery under general anesthesia. 3. Patients undergoing spine surgery with intraoperative neurophysiological monitoring, including motor evoked potentials and/or somatosensory evoked potentials.
Exclusion criteria
  • AddedHistory of epilepsy or electroencephalographic disorder.
  • Edited2. History of epilepsy or electroencephalographic disorder. 3. Use of neuropsychiatric drugs, strong sedatives, or drugs affecting neuromuscular or neurological conduction within 48 hours before surgery.
  • AddedContraindication to intraoperative neurophysiological monitoring.
  • AddedContraindication to rocuronium.
  • Edited5. Contraindication to intraoperative neurophysiological monitoring. 6. Contraindication to rocuronium. 7. Refusal to participate or withdrawal of consent at any time..
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Vietnam
    Show site
    • Bach Mai Hospital · Hanoi, Vietnam
    Start date Jun 2026→Oct 7, 2026 (now actual)
    Eligibility 1 inclusion criterion edited, 2 added; 2 exclusion criteria edited, 3 added
    What changed in the criteria
    Inclusion criteria
    • AddedPatients aged 18 years or older.
    • AddedPatients scheduled for spine surgery under general anesthesia.
    • Edited- 1. Patients aged 18 years or older. 2. Patients scheduled for spine surgery under general anesthesia. 3. Patients undergoing spine surgery with intraoperative neurophysiological monitoring, including motor evoked potentials and/or somatosensory evoked potentials.
    Exclusion criteria
    • AddedHistory of epilepsy or electroencephalographic disorder.
    • Edited2. History of epilepsy or electroencephalographic disorder. 3. Use of neuropsychiatric drugs, strong sedatives, or drugs affecting neuromuscular or neurological conduction within 48 hours before surgery.
    • AddedContraindication to intraoperative neurophysiological monitoring.
    • AddedContraindication to rocuronium.
    • Edited5. Contraindication to intraoperative neurophysiological monitoring. 6. Contraindication to rocuronium. 7. Refusal to participate or withdrawal of consent at any time..
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07627750
Lead sponsor
Bach Mai Hospital
Collaborators
Hanoi Medical University
Responsible party
Nguyen Toan Thang (Principal Investigator, Hanoi Medical University) — Principal investigator
First posted
Jun 4, 2026
Start date
Oct 7, 2026
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Oct 16, 2026

Study contacts

Duc Minh Tran, MD
Contact
tdminh1312@gmail.com
84869319291 ext. 84589916666
Toan Thang Nguyen, MD, PhD, Associate Professor
principal investigator · Hanoi Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rocuronium

Start the discussion